Name	Position	Tenure	Compensation	Ownership
Keith Murphy	Executive Chairman & Corporate Secretary	5.9yrs	US$1.26m	0.38% $ 13.0k
Norman Staskey	President	1.5yrs	US$81.94k	no data
Amar Sethi	Chief Scientific Officer	less than a year	no data	no data
Tony Lialin	Chief Commercial Officer	less than a year	no data	no data

0.8yrs

Average Tenure

55yo

Average Age

Experienced Management: VIVS's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Keith Murphy	Executive Chairman & Corporate Secretary	5.9yrs	US$1.26m	0.38% $ 13.0k
Adam Stern	Independent Director	5.9yrs	US$107.63k	0.17% $ 5.8k
Alison Milhous	Independent Director	5.8yrs	US$115.73k	0.17% $ 5.8k
Douglas Cohen	Lead Independent Director	5.8yrs	US$115.73k	0.20% $ 7.0k
David Gobel	Independent Director	5.8yrs	US$115.73k	no data

5.8yrs

Average Tenure

54yo

Average Age

Experienced Board: VIVS's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/11 17:51
End of Day Share Price	2026/06/11 00:00
Earnings	2025/12/31
Annual Earnings	2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

VivoSim Labs, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Sean Lavin	BTIG
Caroline Corner	Cantor Fitzgerald & Co.
Jose De Jesus Haresco	Citizens JMP Securities, LLC

VivoSim Labs Management

Management criteria checks 1/4

Key information

Recent management updates

VivoSim Labs, Inc. Appoints Amar Sethi as Chief Scientific Officer

VivoSim Labs, Inc., Annual General Meeting, Dec 16, 2025

VivoSim Labs, Inc. Appoints Tony Lialin as Chief Commercial Officer

Insufficient new directors

Organovo Holdings, Inc. Announces Chief Financial Officer Changes

Organovo Holdings, Inc., Annual General Meeting, Nov 20, 2024

Recent updates

VivoSim Labs, Inc. Announces Availability of AI Prediction Tool Leveraging NAMkind Intestinal Models

VivoSim Labs, Inc. has filed a Follow-on Equity Offering.

VivoSim Labs, Inc. Releases Antibody Drug Conjugate Data and Validates NAMkind Models for ADC Toxicity Prediction

Third quarter 2026 earnings released: US$1.03 loss per share (vs US$2.29 loss in 3Q 2025)

VivoSim to Debut Antibody Drug Conjugate Data, Representing A Major New Market for Namkind Models, At Society of Toxicology Meeting in San Diego

VivoSim Labs, Inc. Appoints Amar Sethi as Chief Scientific Officer

New major risk - Financial position

Second quarter 2026 earnings released: US$0.98 loss per share (vs US$1.70 loss in 2Q 2025)

VivoSim Labs, Inc., Annual General Meeting, Dec 16, 2025

VivoSim Labs, Inc. has withdrawn its Follow-on Equity Offering.

New major risk - Share price stability

First quarter 2026 earnings released: US$1.14 loss per share (vs US$2.74 loss in 1Q 2025)

New major risk - Financial position

VivoSim Labs, Inc. Appoints Tony Lialin as Chief Commercial Officer

Full year 2025 earnings released: US$1.70 loss per share (vs US$19.25 loss in FY 2024)

Insufficient new directors

VivoSim Labs, Inc. Presents Best-In-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

Vivosim Labs, Inc. Announces Emergence from Stealth Mode to Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

Organovo Provides Update on Nasdaq Continued Listing Requirements

Eli Lilly and Company (NYSE:LLY) completed the acquisition of FXR Program and Related Assets of Organovo Holdings, Inc. (NasdaqCM:ONVO).

Organovo Announces Reverse Stock Split to Regain Compliance with Minimum Bid Price

Eli Lilly and Company (NYSE:LLY) entered into an asset purchase agreement to acquire FXR Program and Related Assets of Organovo Holdings, Inc. (NasdaqCM:ONVO) for $60 million.

Organovo Holdings, Inc. announced delayed 10-Q filing

Organovo Holdings, Inc. Provides Non-Compliance Update

Organovo Holdings, Inc. Announces Chief Financial Officer Changes

Organovo Holdings, Inc. Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

New minor risk - Share price stability

Consensus EPS estimates upgraded to US$0.75 loss

Organovo Holdings, Inc., Annual General Meeting, Nov 20, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Organovo Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

New minor risk - Share price stability

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2.605728 million.

Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings

New minor risk - Shareholder dilution

New major risk - Market cap size

Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Share price stability

New major risk - Market cap size

Organovo Holdings, Inc., Annual General Meeting, Oct 31, 2023

Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Organovo Holdings, Inc. announced delayed annual 10-K filing

Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

CEO

Leadership Team

Board Members

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources